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Investigation into the frequency of Helicobacter pylori infection with carbon 14 urea
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Background/aim: Vitiligo is a common, acquired depigmenting skin disorder. The relationship between Helicobacter pylori (HP)
infection and autoimmune dermatological disease has been previously reported. However, the frequency of HP infection in patients
with vitiligo has not been reported. In this study, we aimed to investigate the frequency of HP infection with the carbon 14 (C14) urea
breath test (UBT) in patients with vitiligo.
Materials and methods: This study included 34 patients (18 males and 16 females) with vitiligo and 30 age- and sex-matched healthy
controls. HP infection was diagnosed using the C14 UBT (Heliprobe). Statistical analysis was performed using SPSS 19.
Results: The frequency of HP infection was 64.7% in the patient group and 33.3% in the control group according to the C14 UBT (chisquare test, P = 0.012). HP infection frequency is statistically significantly higher in patients with vitiligo.
Conclusion: To the best of our knowledge, this is the first investigation of the frequency of HP positivity in patients with vitiligo. To
better understand the role of HP in vitiligo as an etiological or initiating factor, further experimental and clinical studies with a greater
number of patients are needed.
Key words: Helicobacter pylori, carbon 14, urea breath test, vitiligo

1. Introduction
Vitiligo is an acquired depigmenting skin disorder. It
occurs clinically by the appearance of well-circumscribed,
asymptomatic, white macules following the loss of
functional melanocytes in the epidermis (1). The
prevalence rate of vitiligo ranges from 0.06% to 2.28% in
the population (2). The main etiopathogenesis of vitiligo
is multifactorial. According to various pathophysiological
theories, it may be associated with autoimmunity,
neurogenic dysregulation, autocytotoxicity, biochemical
dysregulation, oxidative stress, and weak melanocyte
viability (1,3–6). Several potentially environmental factors
such as infectious agents appear to be related with vitiligo
(7–9).
Helicobacter pylori (HP) is a major health problem
affecting about 50% of the world population (10). Gastric
ulceration and carcinogenesis are associated with HP
infection (11). HP infection has been linked to various
autoimmune dermatological diseases, such as alopecia
areata, Behçet’s disease, chronic urticaria, pruritus,
psoriasis, and rosacea (12–17). The frequency of HP has
not been studied in patients with vitiligo. Noninvasive
* Correspondence: eminenurrifai@gmail.com

tests such as the carbon 13 or carbon 14 (C14) urea breath
test (UBT), stool antigen tests, and serology are used to
detect HP infection (18). In this study, we used the C14
UBT to detect the frequency of HP infection in patients
with vitiligo.
2. Materials and methods
2.1. Patient and control groups
With the approval of the local ethics committee, a
prospective study was conducted in our dermatology
department clinic. The study comprised 34 patients with
vitiligo and 30 age- and sex-matched healthy controls. The
patients with vitiligo were newly diagnosed and older than
16 years. The patients with gastrointestinal symptoms or
those who had received eradication therapy for HP earlier
were excluded from the study. Other exclusion criteria
were age under 16 years, pregnancy or lactation, and the
use of antibiotics, proton pump inhibitors, or H2 blockers
in the 40, 7, and 14 days, respectively, leading up to sample
collection. According to the working clinical classification,
vitiligo was classified as vitiligo vulgaris, acrofacial, focal,
segmental, universal, or mucosal (16).
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3. Results
Eighteen men and 16 women with vitiligo were included
in this study, in addition to 18 male and 12 female controls.
There was no significant difference between the ages of the
patients and the controls (Table 1). The frequency of HP
infection was 64.7% in the patient group and 33.3% in the
control group with the C14 UBT (Pearson’s chi-square
Table 1. Demographic features and C14 UBT positivity rates of
patients and controls.
Vitiligo

Control

P

Age (years)

48.5 ± 1.9

44.2 ± 2.7

>0.05

Sex (M/F)

18/16

18/12

>0.05

C14 UBT (+/-)

22/12

10/20

<0.05

M = Male, F = female, UBT = urea breath test.
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test, P = 0.012) (Figure). According to the working clinical
classification, the clinical types of vitiligo are shown in
Table 2. The association between autoimmune disease
and vitiligo is described in Table 3. There was no positive
correlation between the presence of autoimmune disease
and HP infection.
4. Discussion
HP is a gram-negative bacterium that colonizes the
gastric mucosa of more than half of the world’s population
(10). HP infection is seen more frequently in developing
countries than in developed countries, perhaps because of
poor health status (21). As a result of gastric colonization
by HP, most infected individuals show histological signs of
chronic gastritis (22). Several studies have reported a link
between HP and systemic diseases (13–17). The incidence
of HP in patients with vitiligo has not been previously
studied. In this study, we found the prevalence of HP to
be 64.7% in the vitiligo group, whereas it was 33.3% in
the control group. The prevalence of HP is significantly
higher in individuals with vitiligo than in their healthy
counterparts in our study. C14 UBT is a reliable and
noninvasive technique for the diagnosis of HP infection.
The sensitivity of the UBT was 96.6%–100% and its
specificity was 76%–100% in different studies (20,23).
However in a study from Turkey, the prevalence of HP
infection was detected as 68% using the C14 UBT in 1680
patients with variable gastrointestinal complaints (24).
In the current study, the prevalence of HP in the control
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2.2. C14 UBT
HP infection was diagnosed using the C14 UBT (Heliprobe
Breath Card TM, Kibion, Uppsala, Sweden). Before the
test, the patients were asked to eat or drink nothing for 6 h.
Antacids and H2 receptor antagonists were discontinued
24 h before the test. One week prior to the test, proton
pump inhibitors and sucralfate were stopped (17).
Antibiotics were discontinued over a month before the test.
Capsules containing 37 kBq (1 µCi) C14 with urea/citric
acid (Helicap, Kibion) were swallowed by the patients with
25 mL of water. Breath specimens were obtained from the
subjects with Heliprobe breath cards (Heliprobe Breath
Card TM, Kibion) 10 min after the patient swallowed the
capsule. Patients insufflated onto the breath card. When its
color indicator changed from orange to yellow, insufflation
was stopped. The breath card was placed into a Geiger
Müller counter (Heliprobe TM analyzer, Kibion). The
C14 activity was counted for 250 s. Results were specified
as counts per minute (cpm). Counts of ≤25 cpm were
described as Heliprobe 0 = not infected, counts of 25–50
cpm were defined as Heliprobe 1 = equivocal, and counts
of ≥50 cpm were classed as Heliprobe 2 = infected. The
thyroid autoantibodies, thyroid stimulating hormone, and
vitamin B12 levels of the patients with vitiligo were also
measured.
2.3. Statistical analyses
All statistical analyses were performed using SPSS 19. Data
were expressed as mean ± standard deviation. Pearson’s
chi-square nonparametric test was used for comparisons
between the groups. P < 0.05 was considered as significant.
Pearson’s correlation and Fisher’s exact test were used to
assess the association between HP and the clinical type of
vitiligo and between HP and autoimmune disease.
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Figure. C14 UBT positivity in patients and controls.
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Table 2. Clinical types of vitiligo seen in this study.
Number of patients

%

Vulgaris

12

35.3

Segmentalis

4

11.8

Acrofacialis

10

29.4

Focalis

3

8.8

Universalis

2

5.9

Mucosal

3

Total

34

Table 3. Related autoimmune diseases of vitiligo and family
history.
Number of
patients

%

Related autoimmune disease

9

26.5

Thyroid autoantibody positivity

7

20.5

Autoimmune chronic urticaria

1

2.9

8.8

Alopecia areata

2

5.9

100

Family history

3

8.8

group was lower compared to the aforementioned studies.
In our study, all patients and controls were asymptomatic
for gastritis. This may explain the lower incidence of HP in
the control group.
The relationship between HP infection and
autoimmune disease has been discussed in many
studies. Chronic urticaria provides the best evidence for
a link between HP infection and autoimmune disease.
For example, Magen et al. divided their patients with
urticaria into 2 groups depending on their resistance
and responsiveness to antihistamines and compared the
incidence of HP positivity with C13 UBT. They found
no statistically significant improvement after eradication
therapy in the 2 groups (25). However, in another study,
IgG antibodies against HP were found to be significantly
higher in patients with urticaria (26). Additionally, Hafez
et al. found a statistically significant difference between
patients with alopecia areata and a control group in
terms of the prevalence of HP infection (27). Meanwhile,
Onsun et al. detected HP infection rates of 59.3% and
61.3%, respectively, in patients with psoriasis and controls
(16). Although they found that HP positivity was not
significantly different between the psoriasis patients
and the controls, they detected a significant correlation
between the severity of psoriasis and HP positivity (16).
The pathogenesis of vitiligo has not been well
documented. However, there is extensive evidence to
support the autoimmune theory. One study reported
that 19.4% of vitiligo patients have a previous history of
autoimmune thyroid disease compared to 2.4% in the
general population (28). In our study, the positivity of
thyroid autoantibody was detected in 20.6% of the vitiligo

group, similar to the literature. In another study from
Turkey, the incidences of alopecia areata and chronic
urticaria in patients with vitiligo were 12.5% and 2.5%,
respectively, and family history was found in 27.5% (29). In
our study, the rates of alopecia areata and chronic urticaria
were found to be 2.7% and 5.5%, respectively.
Infections are responsible for the development of
autoimmunity (30). Microbial agents are involved in
the development of autoimmunity because of their
communication with the environment and the immune
system of the human organism (7). The most commonly
accused infection agents in the etiopathogenesis of vitiligo
are human immunodeficiency virus, hepatitis C virus
(HCV), and cytomegalovirus (CMV) (8,9). However, in a
study by Akbayir et al., HCV RNA was isolated from only 1
patient among 102 subjects with vitiligo (8). Additionally,
Grimes et al. isolated CMV DNA at rates of 31% and 15%,
respectively, from involved and noninvolved skin biopsies,
while the control samples were negative (9).
In conclusion, the limitation of our study was the small
number of patients and controls and the absence of patient
follow-up data after the eradication therapy.
This is the first investigation of the frequency of
HP positivity in patients with vitiligo. Although our
study suggests that HP infection may have a role in the
pathogenesis of vitiligo or may act as a triggering factor,
future studies with larger patient groups are needed to
understand the role of HP in vitiligo as an etiological or
initiating factor. In future studies, the remission rates of
vitiligo should be assessed after HP eradication therapy.
We hope that our study encourages future studies of the
association between vitiligo and HP infection.
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